Leveraging our cutting-edge technology based on protein dynamics, Nutshell is fostering a new
								era of drug discovery…
Our AlloStar allosteric drug discovery platform, composed of a
							powerful and well-integrated set of computational modules and experimental tools based on our proprietary
							AI algorithm and deep know-how derived from biochemistry and biophysics, possesses the unique capability
							to discover a host of drug entities including various types of protein activators, subtype/mutation
							selective small molecules, regulatory molecules of protein-protein interaction (PPI) and stabilizer of
							intrinsically disordered proteins (IDPs), thus opening up an unprecedented new horizon for small molecule
							innovation.


- 
							

Sub-type selective allosteric inhibitor
 - 
							

Mutants selective allosteric inhibitor
 - 
							

Enzyme allosteric activator
 - 
							

Protein-protein interaction modulator
 - 
							

Disordered protein stabilize modulator
 
Current Pipeline
| Project | MoA | Indications | Discovery | Lead to PCC | IND enabling | Phase I/II | Phase III | 
|---|---|---|---|---|---|---|---|
| p53 Y220C | Allosteric activator | Solid tumor | 
									 | 
							||||
| N009 (BIC) | Allosteric inhibitor | Solid tumor | 
									 | 
							||||
| N017 (BIC) | Allosteric inhibitor | Solid tumor | 
									 | 
							||||
| N019 (BIC) | Allosteric inhibitor | Solid tumor | 
									 | 
							||||
| N001 (FIC) | Allosteric activator | Metabolism | 
									 | 
							||||
| Potential FIC projects of various disease targets | 
									 | 
							||||||
Our Lab
						• Building E, No.1976 Middle Gaoke Rd. Pudong District, Shanghai, China
• Unit 308A, Core building 1 (Building 1E),1 Science Park East Ave., HongKong Science Park ,Sha Tin, New Territories, China
contact@allonutshell.com;BD@allonutshell.com
								
								WeChat
							
						Back 
 to the top
